WallStreetZenWallStreetZen

NASDAQ: SNY
Sanofi Stock Forecast, Predictions & Price Target

Open Broker Account

Should I buy or sell SNY stock?

Based on 1 analyst offering ratings for Sanofi.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SNY stock forecasts and price targets.

SNY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Deutsche Bank
Bottom 36%
36
HoldUpgradesN/AN/A2022-08-12

1 of 1

Forecast return on equity

Is SNY forecast to generate an efficient return?
Company
9.27%
Industry
92.8%
Market
122.96%
SNY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SNY forecast to generate an efficient return on assets?
Company
5.4%
Industry
17.91%
SNY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SNY earnings per share forecast

What is SNY's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$4.09+46.33%
Avg 2 year Forecast
$4.26+52.42%
Avg 3 year Forecast
$4.70+68.16%
SNY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

SNY revenue forecast

What is SNY's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$45.4B+2.57%
Avg 2 year Forecast
$47.4B+7.18%
Avg 3 year Forecast
$49.7B+12.28%
SNY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SNY earnings growth forecast

How is SNY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
20.56%
Industry
13.76%
Market
17.18%
SNY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
SNY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
SNY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

SNY revenue growth forecast

How is SNY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
5.37%
Industry
1%
Market
8.5%
SNY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SNY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SNY vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
SNY$38.90N/AN/AHold
GILD$64.95$71.79+10.53%Buy
AMGN$230.94$239.50+3.71%Hold
GSK$30.00N/AN/AHold
BMY$70.24$75.90+8.06%Buy

Sanofi Stock Forecast FAQ

Is Sanofi Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SNY) stock is to Hold SNY stock.

Out of 1 analyst, 0 (0%) are recommending SNY as a Strong Buy, 0 (0%) are recommending SNY as a Buy, 1 (100%) are recommending SNY as a Hold, 0 (0%) are recommending SNY as a Sell, and 0 (0%) are recommending SNY as a Strong Sell.

If you're new to stock investing, here's how to buy Sanofi stock.

What is SNY's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: SNY) Sanofi's current Earnings Per Share (EPS) is $2.68. On average, analysts forecast that SNY's EPS will be $4.09 for 2022, with the lowest EPS forecast at $4.00, and the highest EPS forecast at $4.17. On average, analysts forecast that SNY's EPS will be $4.26 for 2023, with the lowest EPS forecast at $4.06, and the highest EPS forecast at $4.38. In 2024, SNY's EPS is forecast to hit $4.70 (min: $4.61, max: $4.77).

What is SNY's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: SNY) forecast ROE is 9.27%, which is considered weak.

What is SNY's earnings growth forecast for 2022-2024?

(NASDAQ: SNY) Sanofi's forecast annual earnings growth rate of 20.56% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 13.76%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 17.18%.

Sanofi's earnings in 2022 is $6,710,101,010.On average, 3 Wall Street analysts forecast SNY's earnings for 2022 to be $5,167,963,243, with the lowest SNY earnings forecast at $5,054,242,780, and the highest SNY earnings forecast at $5,269,048,098. On average, 5 Wall Street analysts forecast SNY's earnings for 2023 to be $5,382,768,561, with the lowest SNY earnings forecast at $5,130,056,422, and the highest SNY earnings forecast at $5,534,395,844.

In 2024, SNY is forecast to generate $5,938,735,267 in earnings, with the lowest earnings forecast at $5,825,014,804 and the highest earnings forecast at $6,027,184,515.

What is SNY's revenue growth forecast for 2022-2024?

(NASDAQ: SNY) Sanofi's forecast annual revenue growth rate of 5.37% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.5%.

Sanofi's revenue in 2022 is $42,463,636,363.On average, 3 Wall Street analysts forecast SNY's revenue for 2022 to be $57,352,421,018,281, with the lowest SNY revenue forecast at $57,099,284,322,887, and the highest SNY revenue forecast at $57,658,473,108,459. On average, 3 Wall Street analysts forecast SNY's revenue for 2023 to be $59,926,728,818,875, with the lowest SNY revenue forecast at $59,627,808,265,259, and the highest SNY revenue forecast at $60,276,166,529,077.

In 2024, SNY is forecast to generate $62,779,751,574,011 in revenue, with the lowest revenue forecast at $62,135,875,159,978 and the highest revenue forecast at $63,887,738,885,561.

What is SNY's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: SNY) forecast ROA is 5.4%, which is lower than the forecast US Drug Manufacturers - General industry average of 17.91%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.